Rivastigmine, developed by Novartis, is an innovative drug for the treatment of Alzheimer's and Parkinson's dementia. Rivastigmine is administered in the form of a transdermal patch, providing a convenient and continuous drug treatment method.
What is Rivastigmine?
Understanding the drug information of Rivastigmine can accurately guide treatment, improve efficacy and reduce adverse reactions.
Basic information and R&D background
Rivastigmine, English name Rivastigmine, trade name Exelon Patch, was developed by Novartis and launched in the United States in July 2007. The drug provides a new treatment option for patients with Alzheimer's and Parkinson's dementia with its unique transdermal delivery method. Rivastigmine has not yet been launched in China and has not been included in the medical insurance catalog, but patients can obtain it through regular medical service institutions or cross-border e-commerce platforms.
Drug ingredients
The main ingredient of the Rivastigmine transdermal patch is Rivastigmine, an acetylcholinesterase inhibitor. It inhibits the activity of acetylcholinesterase and reduces the decomposition of acetylcholine, thereby increasing the level of acetylcholine in the brain. This mechanism helps improve cognitive function and relieve symptoms in patients with Alzheimer's and Parkinson's dementia.
Dosage form
Rivastigmine transdermal patches are available in a variety of strengths, including 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours, to meet the treatment needs of different patients.
Rivastigmine transdermal patch (Rivastigmine) treatment effect
Understanding the effect of drug treatment can adjust the treatment plan in time, ensure that patients get the best effect and promote the recovery process.
Indications
Rivastigmine transdermal patches are mainly used to treat mild to moderate Alzheimer's and Parkinson's dementia. Clinical studies have shown that the drug can significantly improve patients' cognitive function, daily living ability and behavioral symptoms.
Efficacy
By increasing the level of acetylcholine in the brain, rivastigmine transdermal patches help restore patients' memory, attention and language ability, and reduce psychiatric symptoms such as anxiety and depression. The drug can also delay disease progression and improve patients' quality of life.
Dose titration
The therapeutic effect of rivastigmine transdermal patches is closely related to the dose. The initial dose is usually 4.6mg/24 hours, and then the dose is gradually increased according to the patient's tolerance and therapeutic effect. The dose titration process should be carried out carefully to avoid adverse reactions.
By in-depth understanding of the basic information of rivastigmine transdermal patches, patients can better use this innovative drug to provide more effective treatment options for patients with Alzheimer's and Parkinson's dementia.
